Thyroid Diseases

14

Review clinical trials related to Thyroid Diseases. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Postoperative Pain of Robotic, Endoscopic and Open Lateral Neck Dissection

Postoperative pain is a good indicator to confirm the advantages of the surgical methods in the era of minimally invasive surgery. Lateral neck dissection requires extensive dissection which may leads to postoperative numbness and pain. Robotic thyroid surgery has the advantage of precise and careful dissection and avoid the L-shape incision in the open approach. The study aims to explore the pain intensity and severity of lateral neck dissection on operation day, postoperative month 1 and postoperative month 3 among the robotic, endoscopic and open approach.

Participants needed: 600
Trial details
Biological sex: AllType: ObservationalSponsor: Shanghai 6th People's HospitalUpdated: Jun 24, 2026Locations: 1Duration: 6 Months
Eligibility criteria

Patients underwent lateral neck dissection via robotic, endoscopic or open appro... [+2]

Participants with distant metastasis [+2]

Status: Not yet recruiting

Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery

This study aims to evaluate the performance of the PTAIR computer vision model for recognizing parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery. Multicenter intraoperative endoscopic surgery videos will be prospectively collected. Using the video recorder timeline as the unified time reference, the first recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR, junior physicians, and senior physicians will be recorded during surgery. The continuous recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR will also be recorded. This study focuses on the recognition performance of PTAIR in real-world multicenter endoscopic thyroid surgery settings. At this stage, PTAIR will not be used to guide intraoperative surgical decision-making, and the study will not evaluate the effect of PTAIR on clinical outcomes. The collected video data will be used to assess the performance of PTAIR under different centers, surgeons, equipment conditions, and surgical field conditions, and may provide data support for future model optimization.

Participants needed: 100
Trial details
Biological sex: AllType: ObservationalSponsor: Fujian Medical UniversityUpdated: Jun 5, 2026Locations: 1
Eligibility criteria

Age 18 years or older. [+5]

Refusal to provide informed consent. [+8]

Status: Not yet recruiting

NIRAF-Guided Parathyroid Identification During Thyroidectomy

This is a single-site, two-component prospective study evaluating whether near-infrared autofluorescence (NIRAF) imaging can improve intraoperative identification of parathyroid glands during thyroidectomy and reduce postoperative hypocalcemia. The investigational platform is a modified wearable stereoscopic goggle system configured for label-free NIRAF imaging. Parathyroid tissue is excited with near-infrared light at approximately 780 nm and emits autofluorescence centered near 800 nm. No injected dye or external contrast agent is used. The goggles are used only during a brief mapping interval after thyroid exposure and for ex vivo interrogation of the resected thyroid specimen. Component A is a prospective observational run-in validation cohort of 30 adults undergoing thyroidectomy of any extent. NIRAF-positive foci on the intact thyroidectomy specimen are suture-marked and correlated with targeted pathology. Component B is a randomized clinical study of 250 adults undergoing total or completion thyroidectomy. Participants are randomized 1:1 to standard surgery or standard surgery plus brief in vivo NIRAF mapping, ex vivo specimen interrogation, and rescue autotransplantation when indicated. The primary outcome for Component B is transient biochemical hypocalcemia on postoperative day 1, defined using albumin-corrected serum calcium.

Participants needed: 280
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Ss. Cyril and Methodius University of SkopjeUpdated: Jun 1, 2026Locations: 1
Eligibility criteria

Age 18 years or older. [+4]

Known pre-existing hypoparathyroidism or prior parathyroid surgery. [+4]

Status: Recruiting

Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)

To develop and validate a structured scoring tool (robotic thyroidectomy assessment score, RTAS) for assessing and quantifying surgical performance in robotic thyroidectomy (RT).

Participants needed: 200
Trial details
Biological sex: AllType: ObservationalSponsor: Shanghai 6th People's HospitalUpdated: May 7, 2026Locations: 1Duration: 6 Months
Eligibility criteria

Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not... [+3]

Participants with history of neck surgery or radiation [+3]

Status: Recruiting

Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy

The investigators have previously proposed a prediction model for difficult transoral and submental thyroidectomy through a retrospective study. In order to better promote transoral and submental endoscopic approach for thyroid surgery and to set up an appropriate training course, the investigators aim to renovate and validate the prediction model through a prospective study.

Participants needed: 300
Trial details
Biological sex: AllType: ObservationalSponsor: Shanghai 6th People's HospitalUpdated: May 7, 2026Locations: 1
Eligibility criteria

Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not... [+2]

Participants with fusion or fixation of lymph nodes in the neck [+4]

Status: Recruiting

Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery

Thyroid surgery requires smooth emergence from anesthesia to minimize coughing, hemodynamic fluctuations, and agitation during extubation, which may contribute to postoperative complications such as bleeding or cervical hematoma. Dexmedetomidine, a selective α2-adrenergic receptor agonist, has sedative, analgesic-sparing, and sympatholytic properties that may improve anesthetic stability and recovery quality. This randomized controlled trial aims to evaluate the effectiveness of a continuous perioperative dexmedetomidine regimen initiated at induction of anesthesia and maintained during thyroid surgery. The study will compare dexmedetomidine combined with standard balanced anesthesia versus standard anesthesia alone in terms of anesthetic requirements and emergence quality. The primary hypothesis is that perioperative dexmedetomidine administration reduces anesthetic and opioid requirements and improves emergence quality by decreasing coughing during extubation and hemodynamic responses.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18-65Biological sex: AllType: InterventionalSponsor: Bach Mai HospitalUpdated: Apr 15, 2026Locations: 1
Eligibility criteria

Age 18-65 years. [+3]

Known hypersensitivity or contraindication to dexmedetomidine or study-related m... [+6]

Status: Recruiting

Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

* Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months. * Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting in a significant deterioration in quality of life. * The intraoperative use of indocyanine green (ICG) angiography has recently been described as a reliable means of detecting parathyroidism and predicting the risk of postoperative hypoparathyroidism. * This use could prove to be a way to preserve parathyroid in vivo and thus reduce post-operative hypoparathyroidism rates.

Participants needed: 242
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, BrestUpdated: Mar 19, 2026Locations: 1
Eligibility criteria

Patient having to undergo a total thyroidectomy [+2]

Minor patient under 18 years old [+7]

Status: Recruiting

Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control

The goal of this clinical trial is to evaluate the therapeutic efficacy and safety of non-thermal plasma (NTP) as an adjuvant treatment for surgical bed decontamination and accelerated tissue repair in patients undergoing total thyroidectomy. The study aims to address the following objectives: * Does the intraoperative application of NTP to the surgical bed and closed incision promote accelerated tissue regeneration compared to conventional postoperative care? * Does NTP treatment reduce postoperative inflammatory response, pain intensity, and the incidence of site-specific complications (such as surgical site infection or seroma)? * What is the safety profile of helium-based NTP in the cervical anatomical region regarding neighboring neurovascular structures? Participants will be randomized into two arms: 1. The experimental group: Receiving a standardized application of helium-based NTP (at a frequency of 13.56 MHz) to the surgical bed prior to closure and subsequently to the sutured incision. 2. The control group: Receiving standard-of-care surgical wound management. Clinical follow-up will include quantitative assessment of healing rates, pain scales (VAS), and biochemical or clinical markers of inflammation at scheduled intervals (Days 1, 7, 15, and up to 12 weeks post-surgery).

Participants needed: 26
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: National Institute of Nuclear Research - MexicoUpdated: Feb 9, 2026Locations: 1
Eligibility criteria

Patients aged 18 years or older. [+3]

History of previous neck surgery or radiation therapy in the cervical area. [+5]

Status: Recruiting

Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis

Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.

Participants needed: 100
Trial details
Biological sex: AllType: ObservationalSponsor: Guang'anmen Hospital of China Academy of Chinese Medical SciencesUpdated: Dec 24, 2025Locations: 1
Eligibility criteria

Patients with an initial diagnosis of rheumatoid arthritis (RA). [+2]

Patients subsequently confirmed not to have RA during the study.

Status: Recruiting

Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease

Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to explore immunological markers possibly associated with mental fatigue in Graves' disease, which the investigators plan to validate in another study (ImmunoGraves wp 2). Using a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of Graves disease. The patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. SciLifeLab in Stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. Serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. Proteins that preferably bind to antibodies in sera and/or cerebrospinal fluid from Graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the Human Protein Atlas and the Allen brain map to identify those proteins that are expressed in the brain. Antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.

Participants needed: 180
Trial details
Age: 18-72Biological sex: FemaleType: ObservationalSponsor: Vastra Gotaland RegionUpdated: Sep 29, 2025Locations: 1
Eligibility criteria

If patient: Graves' disease with positive TSH-receptor antibodies and thyroid ho... [+5]

Person unable to follow protocol [+6]

Status: Recruiting

Prospective Evaluation of OptiThyDose

The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).

Participants needed: 150
Trial details
Age: Up to 18Biological sex: AllType: InterventionalSponsor: University Children's Hospital BaselUpdated: Sep 3, 2025Locations: 2
Eligibility criteria

Newborns with pathological neonatal screening and confirmation of an increased T... [+4]

Exclusion of newborns from mothers with GD [+5]

Status: Recruiting

Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens

The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants. The study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.

Participants needed: 4,094
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Shanghai Changzheng HospitalUpdated: Sep 8, 2025Locations: 1Duration: 10 Years
Eligibility criteria

The 4,094 residents of Shanghai communities who have been enrolled in the STONE... [+2]

Participants who have moved away from their original community and have been liv... [+1]

Status: Recruiting

Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC

This study is a multicenter, non-inferiority, open-label, randomized controlled Phase III clinical trial. It aims to compare the efficacy of modified delineation radiotherapy (experimental group) versus standard delineation radiotherapy (control group) in the prophylactic irradiation of neck lymphatic drainage areas III/IVa in nasopharyngeal carcinoma. The study evaluates the incidence of primary hypothyroidism, quality of life, and adverse events between the two groups.

Participants needed: 474
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Jiangxi Provincial Cancer HospitalUpdated: Apr 10, 2025Locations: 1
Eligibility criteria

History of other malignant tumors (excluding basal cell carcinoma/squamous cell... [+5]

Status: Recruiting

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

Participants needed: 75
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Sling Therapeutics, Inc.Updated: Feb 25, 2025Locations: 2
Eligibility criteria

Subject who completed the 24-week double-mask period of VGN-TED-301 and are prop... [+3]

The exclusion criteria of protocol VGN-TED-301 also apply to this extension stud...